Pancragen vs GHK
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- GHK is the natural tripeptide (Gly-His-Lys) released from human albumin that activates tissue remodeling, collagen synthesis, and anti-aging gene expression. The copper-free form is the biological signaling molecule; it chelates copper in tissue to form GHK-Cu but also has independent biological activity.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Extremely short as free peptide; tissue binding extends local effects
- Admin Route
- SubQ, Oral
- SubQ, Topical, Oral
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 100–500 mcg
- Frequency
- Daily for 10–30 days
- Daily or 5x per week
- Key Benefits
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Stimulates collagen and extracellular matrix synthesis
- Activates tissue repair gene expression programs
- Anti-aging: reverses 57% of age-related gene changes
- Antioxidant and anti-inflammatory
- Wound healing and skin barrier repair
- Improves skin laxity, texture, and radiance
- Neuroprotective (stimulates NGF, BDNF)
- Anti-fibrotic in liver and lung models
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Excellent safety profile (naturally occurring peptide)
- Rare: mild injection site reaction (SC)
- No significant adverse effects identified in research
- Stacks With
- —
- —